Erlotinib hydrochloride

한글명:Erlotinib hydrochloride

카스 번호183319-69-9

상품명:Erlotinib hydrochloride

CBNumberCB2285915

분자식C22H24ClN3O4

포뮬러 무게429.9

MOL 파일183319-69-9.mol

화학적 성질

녹는점	223-225°C
저장 조건	Inert atmosphere,Store in freezer, under -20°C
용해도	DMSO에 용해됩니다(가온 시 최대 18mg/ml).
물리적 상태	노란색 가루.
산도 계수 (pKa)	pKa (25°): 5.42
색상	흰색 또는 황백색
안정성	제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO의 솔루션은 -20°에서 최대 3개월 동안 보관할 수 있습니다.
InChI	InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
InChIKey	GTTBEUCJPZQMDZ-UHFFFAOYSA-N
SMILES	C12C=C(OCCOC)C(OCCOC)=CC=1N=CN=C2NC1=CC=CC(=C1)C#C.Cl
CAS 데이터베이스	183319-69-9(CAS DataBase Reference)

위험 및 안전 성명

안전지침서

24/25

HS 번호

29335990

NFPA 704:

	0
3		0

그림문자(GHS)

Erlotinib hydrochloride 화학적 특성, 용도, 생산

화학적 성질
Off-White Solid
용도
Erlotinib hydrochloride (V), a quinazoline derived small molecule inhibitor of epidermal growth factor receptor (EDGFR) tyrosine kinase, was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer. It belongs to the same class as gefitinib,another quinazoline approved for treatment of advanced lung cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development initiated in collaboration with OSI, which assumed full rights to the drug when Pfizer merged with Warner Lambert. Subsequently, Genentech/Roche went into licensing agreement with OSI to develop and market the drug in the US and Worldwide.
정의
ChEBI: A quinazoline hydrochloride compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.
일반 설명
Erlotinib is available as 25-, 100-, and 150-mg tablets fororal administration and is used after failure of first-linetherapy in metastatic NSCLC and as first-line therapy incombination with gemcitabine in the treatment of metastaticpancreatic cancer, and in treating malignant gliomas.The structural similarity to gefitnib imparts similar pharmacokineticbehavior with bioavailability of 60% and proteinbinding of 93%. The agent is extensively metabolizedprimarily by CYP3A4. Three major metabolic pathwayshave been identified, involving oxidative-O-demethylationof the side chains followed by further oxidation to give thecarboxlic acids, oxidation of the acetylene functionalityto give a carboxylic acid, and aromatic hydroxylation ofthe phenyl ring para to the electron-donating nitrogen. Themetabolites are primarily eliminated in the feces, and theterminal half-life is 36 hours.The major toxicities seenwith the agent are dose-limiting skin rash and diarrhea.Other common adverse effects include shortness of breath,fatigue, and nausea.

Erlotinib hydrochloride 준비 용품 및 원자재

Erlotinib hydrochloride 공급 업체

Erlotinib hydrochloride 관련 검색

Send Inquriy